Reframe Daily: Shot helps prevent first heart attacks; one-time gene edit lowers bad fats

Reframe Daily—curated by Christin Chong (neuroscience PhD, Buddhist chaplain, healthtech strategy consultant)—delivers optimistic and credible health research updates you won’t find in most popular news outlets, from sources scientists and healthcare providers read and trust.

Today in one sentence: Trials this week showed earlier heart protection with an approved shot, powerful fat-lowering from a single gene edit, real gains from a late-stage kidney drug, fresh hope against hepatitis D, and the FDA removed black box warning for women’s hormone replacement therapy.

Pop in the Discord to chat about health →
https://forms.gle/tN3oabFTsDF21VnS8

Personal shares from Christin here →
http://christin.substack.com/

Good news: A widely available cholesterol‑lowering shot prevented first heart attacks and strokes in high‑risk people who hadn’t had one yet.

Evolocumab in Patients without a Previous Myocardial Infarction or Stroke

Market readiness: 🙂🙂🙂🙂🙂 (on‑market PCSK9 antibody; this large RCT shows benefit for earlier use in high‑risk adults without prior events—clinicians can act now while label/guideline updates are considered). 

Good news: A monthly RNA‑targeting drug slashed very high triglycerides and cut pancreatitis risk—giving people a safer path to avoid dangerous flare‑ups.

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

Market readiness: 🙂🙂🙂🙂 (drug is already FDA‑approved for FCS; these phase 3 trials in severe hypertriglyceridemia show strong benefit, positioning it for broader use though that indication isn’t approved yet). 

Good news: An immune‑targeting antibody cut kidney protein loss in IgA nephropathy—an early sign treatment may slow damage.

Sibeprenlimab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial

Market readiness: 🙂🙂🙂🙂 (late‑stage therapy under FDA Priority Review with a target action date of Nov 28, 2025; if approved, US availability would be imminent). 

Good news: A 2‑drug approach for hepatitis D pushed virus levels down in many patients—promising for a very hard‑to‑treat infection.

A Phase 2 Trial of Tobevibart plus Elebsiran in Hepatitis D

Market readiness: 🙂🙂 (mid‑stage trial; combo isn’t approved yet, but a registrational program is underway). 

Good news: A one‑time CRISPR gene‑editing infusion lowered “bad” cholesterol and triglycerides in people—hinting at a future where a single treatment could manage lifelong risk.

Phase 1 Trial of CRISPR‑Cas9 Gene Editing Targeting ANGPTL3

Market readiness: 🙂 (first‑in‑human, early‑phase study; exciting but years from consumer availability pending larger safety/efficacy trials). 

FDA item of the day

HHS Removes Black Box FDA Warnings on Hormone Replacement Therapy — FDA Newsroom press announcement dated Nov 10, 2025. Press Announcements hub

Thank you for taking the time to take care of yourself and your loved ones.